Updated · 7 min read
What Is Continuous Glucose Monitoring and the Role of Connected Devices?
Continuous glucose monitoring (CGM) tracks blood glucose levels in real time through a small sensor worn on the body. The sensor measures glucose in interstitial fluid and sends readings at regular intervals to a connected device. This device displays trends, alerts users to highs and lows, and shares data with caregivers or clinical systems. The connected component may be a dedicated receiver, a smartphone, a tablet, or a purpose-built medical device gateway that aggregates multiple health data streams.
A complete CGM system has three core parts: the wearable sensor with a transmitter, the connected device that receives and processes data, and the software layer that stores, analyzes, and distributes that information. The sensor typically lasts several days to two weeks. The connected device serves as the critical link between patient and care team, making its reliability, security, and integration capabilities central to effective diabetes management.
Healthcare providers, medical device manufacturers, and enterprise mobility teams need to understand how CGM connected devices function. Endocrinology practices use CGM data to adjust insulin therapy. Product teams building diabetes management platforms must decide which devices will host their applications. IT and operations groups must ensure these devices integrate with electronic health record (EHR) systems, comply with healthcare regulations, and remain manageable at scale.
The Connected Device Governs Data Reliability
The sensor generates glucose readings, but the connected device determines what happens next. It manages Bluetooth pairing, handles encryption, stores readings during connectivity gaps, and transmits information to cloud platforms or EHR systems. A device with poor antenna design, inconsistent Bluetooth performance, or inadequate battery life can interrupt the data stream and create dangerous monitoring gaps.
For home-based patients, the connected device is their primary interface for understanding glucose trends. For clinicians in remote patient monitoring (RPM) programs, the device must feed data into centralized dashboards without manual intervention. The same sensor paired with different connected devices can produce different clinical outcomes depending on transmission reliability, storage capacity, and alert functionality.
Hardware and Software Decisions for CGM Programs
Teams developing or deploying CGM connected devices face interconnected decisions. The hardware form factor affects patient adherence: a dedicated handheld may offer better battery life and physical buttons for elderly users, while a smartphone application reduces device count. The software architecture determines whether the device runs locked-down, single-purpose configurations or remains open to applications that introduce distraction and security exposure.
Connectivity choices also matter. Bluetooth Low Energy (BLE) is standard for sensor-to-device communication, but backhaul from device to cloud may use Wi-Fi, cellular, or both. Cellular connectivity enables monitoring during travel or in areas without reliable Wi-Fi, but requires carrier certification and data plan management. The RHINO M3501 5G RedCap module, certified for AT&T's network, illustrates how purpose-built cellular modules can support healthcare IoT with lower power consumption and smaller form factors than full 5G.
Integration Requirements for Clinical Workflows
CGM data gains value when it flows into clinical workflows rather than remaining isolated on a patient-facing screen. Integration requires application programming interfaces (APIs) that push structured glucose data into EHR systems, population health platforms, or care team dashboards. The connected device must support encryption at rest and in transit, plus authentication mechanisms that satisfy healthcare compliance requirements.
Device management capabilities become essential at scale. A health system deploying hundreds of CGM connected devices needs centralized configuration, remote updates, and the ability to lock devices to approved applications. Android Enterprise provides frameworks for dedicated device deployments that restrict functionality to clinical use cases, reduce attack surfaces, and enable zero-touch provisioning.
Security, Compliance, and Regulatory Pathways
CGM data qualifies as protected health information (PHI) under HIPAA in the United States and comparable regulations elsewhere. The connected device must maintain audit trails, support access controls, and enable remote wipe if lost or stolen. Devices not configured for enterprise management typically lack these safeguards, creating compliance exposure.
The Food and Drug Administration (FDA) may regulate the connected device as part of the CGM system if it performs data processing or display functions affecting clinical decision-making. Product teams must determine early whether their device requires 510(k) clearance or falls under enforcement discretion. This classification affects development timelines, validation requirements, and design documentation needs.
Evaluating CGM Connected Device Options
| Evaluation Area | Question to Ask | Operational Impact |
|---|---|---|
| Connectivity reliability | Does the device maintain sensor pairing through daily movement, sleep, and travel? | Data gaps delay hypoglycemia or hyperglycemia alerts |
| Battery performance | Will the device last a full day with continuous BLE polling and periodic data transmission? | Patients abandon devices requiring midday charging |
| Management capability | Can IT configure, update, and secure devices remotely without patient intervention? | Scaled deployments need centralized control |
| Clinical integration | Does the platform expose APIs for EHR or care team dashboard integration? | Isolated data limits clinical value |
| Regulatory pathway | Is the connected device classified as a medical device requiring FDA clearance? | Unanticipated requirements can delay launch |
When Purpose-Built Devices Become Necessary
Consumer smartphones can function as CGM displays for individual patients, but healthcare organizations and device manufacturers often require more control. Purpose-built medical device gateways aggregate data from multiple sensors, including CGMs, pulse oximeters, and blood pressure monitors, into a single managed endpoint. This consolidation reduces patient device burden, simplifies charging and support, and creates unified data streams for clinical teams.
A patient with multiple chronic conditions might otherwise carry separate devices for each sensor, each with distinct charging requirements and failure points. A purpose-built gateway replaces this fragmentation with one device designed for clinical reliability.
Frequently Asked Questions
What is the difference between a CGM sensor and a CGM connected device?
The sensor measures glucose in interstitial fluid. The connected device receives, displays, stores, and transmits that data. The sensor generates the reading; the connected device determines whether that reading reaches the patient, caregiver, or clinical system reliably and securely.
Why does Bluetooth connectivity matter so much for CGM performance?
Bluetooth Low Energy (BLE) transmits data from sensor to connected device. Inconsistent BLE performance causes data gaps and missed alerts. Device antenna design, firmware stability, and interference management affect whether the connection remains stable through daily activities.
When should a healthcare organization choose a dedicated CGM device over a patient-owned smartphone?
Dedicated devices become preferable when centralized management, regulatory compliance, or patient population needs require controlled configurations. Elderly patients or those with limited technology familiarity often benefit from simplified, locked-down devices. Organizations deploying at scale gain efficiency through unified management.
What regulatory requirements apply to CGM connected devices?
If the connected device processes, displays, or transmits glucose data for clinical decision-making, it may require FDA 510(k) clearance as part of the CGM system. Even when not directly regulated, the device must satisfy HIPAA requirements for protected health information.
How does 5G RedCap benefit CGM and remote patient monitoring?
5G RedCap (Reduced Capability) offers lower power consumption and smaller module size than full 5G while maintaining 5G security and latency advantages. For CGM connected devices needing cellular backhaul without flagship 5G cost and battery demands, RedCap enables longer device life and more compact designs.
What should product teams prioritize when designing a new CGM connected device?
Requirements definition should start with the clinical workflow: who receives the data, how quickly they need it, and what actions follow abnormal readings. Starting with hardware specifications rather than workflow needs often produces devices that technically function but fail to fit clinical practice.
Connected Devices Complete the CGM System
Continuous glucose monitoring advances diabetes care, but the sensor is only the beginning. The connected device governs data reliability, security, clinical integration, and patient experience. Product teams, IT leaders, and healthcare operators evaluating CGM systems should look past sensor specifications to assess how effectively the connected device serves the full data journey from patient to clinical decision-maker.
NEXA develops custom healthcare mobility solutions and purpose-built medical device gateways that connect sensors to clinical systems with enterprise-grade security and management. From Android Enterprise device programs to 5G RedCap connectivity modules, NEXA supports healthcare organizations and device manufacturers in building connected diabetes management solutions that perform reliably at scale. Contact NEXA to discuss engineering your CGM connected device program for clinical workflow integration and long-term fleet management.
This content may have been generated in whole or in part using artificial intelligence tools. While reviewed for accuracy prior to publication, NEXA makes no warranties regarding the completeness or reliability of AI-assisted content and disclaims liability for errors or omissions. This content is for general informational purposes. NEXA disclaims liability for errors, omissions, or outcomes resulting from reliance on this content.